TESARO, Inc. (NASDAQ:TSRO) was downgraded by research analysts at BidaskClub from a “hold” rating to a “sell” rating in a report released on Friday.

TSRO has been the topic of a number of other reports. Janney Montgomery Scott set a $139.00 price target on TESARO and gave the stock a “hold” rating in a research report on Saturday, June 10th. Cowen and Company set a $145.00 price target on TESARO and gave the stock a “hold” rating in a research report on Saturday, June 10th. FBR & Co reduced their price target on TESARO from $200.00 to $195.00 and set a “mkt perform” rating on the stock in a research report on Monday, June 5th. Cann reaffirmed a “buy” rating and set a $199.00 price target on shares of TESARO in a research report on Monday, June 5th. Finally, Robert W. Baird reaffirmed a “neutral” rating on shares of TESARO in a research report on Tuesday, June 6th. One research analyst has rated the stock with a sell rating, nine have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. TESARO has a consensus rating of “Buy” and a consensus target price of $173.68.

TESARO (NASDAQ TSRO) traded down 0.69% on Friday, reaching $140.02. The company had a trading volume of 569,574 shares. The company’s market capitalization is $7.54 billion. The stock’s 50-day moving average is $146.21 and its 200-day moving average is $151.73. TESARO has a 52 week low of $80.35 and a 52 week high of $192.94.

TESARO (NASDAQ:TSRO) last posted its earnings results on Tuesday, May 9th. The biopharmaceutical company reported ($2.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($2.26) by $0.29. The company had revenue of $3.10 million for the quarter, compared to analysts’ expectations of $3.84 million. TESARO had a negative return on equity of 96.49% and a negative net margin of 910.35%. The firm’s quarterly revenue was up 909.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($2.22) EPS. Equities research analysts forecast that TESARO will post ($8.74) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This report was published by American Banking News and is the sole property of of American Banking News. If you are accessing this report on another site, it was copied illegally and reposted in violation of United States & international copyright law. The correct version of this report can be viewed at https://www.americanbankingnews.com/2017/06/30/bidaskclub-downgrades-tesaro-inc-nasdaqtsro-to-sell.html.

In other TESARO news, VP Edward C. English sold 8,500 shares of the stock in a transaction dated Tuesday, June 6th. The stock was sold at an average price of $138.65, for a total transaction of $1,178,525.00. Following the sale, the vice president now directly owns 5,396 shares of the company’s stock, valued at approximately $748,155.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Martin H. Jr. Huber sold 829 shares of the stock in a transaction dated Monday, April 3rd. The stock was sold at an average price of $153.02, for a total value of $126,853.58. Following the sale, the senior vice president now directly owns 6,522 shares in the company, valued at $997,996.44. The disclosure for this sale can be found here. 40.50% of the stock is currently owned by company insiders.

A number of large investors have recently made changes to their positions in TSRO. FMR LLC increased its stake in shares of TESARO by 0.4% in the first quarter. FMR LLC now owns 8,043,921 shares of the biopharmaceutical company’s stock valued at $1,237,718,000 after buying an additional 32,918 shares in the last quarter. BlackRock Inc. increased its stake in shares of TESARO by 4,504.8% in the first quarter. BlackRock Inc. now owns 3,409,657 shares of the biopharmaceutical company’s stock valued at $524,643,000 after buying an additional 3,335,611 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of TESARO by 3.7% in the first quarter. Vanguard Group Inc. now owns 2,916,132 shares of the biopharmaceutical company’s stock valued at $448,705,000 after buying an additional 103,759 shares in the last quarter. State Street Corp increased its stake in shares of TESARO by 0.4% in the first quarter. State Street Corp now owns 991,856 shares of the biopharmaceutical company’s stock valued at $152,617,000 after buying an additional 3,784 shares in the last quarter. Finally, Bank of New York Mellon Corp increased its stake in shares of TESARO by 35.0% in the first quarter. Bank of New York Mellon Corp now owns 675,597 shares of the biopharmaceutical company’s stock valued at $103,954,000 after buying an additional 175,273 shares in the last quarter.

About TESARO

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company operates through the business of developing and commercializing of oncology-focused therapeutics segment. It is developing oncology-related product candidates, including rolapitant, niraparib and the product candidates under its immuno-oncology platform.

Analyst Recommendations for TESARO (NASDAQ:TSRO)

Receive News & Ratings for TESARO Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TESARO Inc. and related companies with MarketBeat.com's FREE daily email newsletter.